Collectively, our results highlight the role of RTX-IgG2 as an exclusive and target-specific enhancer for FcR-mediated phagocytosis of CD20+ B-cell lymphoma cells, an effect associated with induction of apoptosis and reduction of CD47 on target cells. This evidence concerns the gene CD47 and B-cell non-Hodgkin lymphoma.